文献速递抗栓抗凝管理药物相互作用

达比加群双联与华法林三联在房颤PCI术后患者中的比较:质子泵抑制剂使用的事前分析

Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
PubMed 文献 · Drugs · 2020-01-01

RE-DUAL PCI试验的事前亚组分析,纳入2725例房颤PCI术后患者,按基线质子泵抑制剂使用情况评估达比加群双联(110或150mg每日两次)与华法林三联的出血和疗效终点。结果显示,无论是否使用质子泵抑制剂,达比加群双联均降低大出血或临床相关非大出血风险,疗效复合终点相似,胃肠道出血无交互作用。

要点

  • 达比加群双联较华法林三联降低出血风险,不受基线PPI使用影响。
  • 复合疗效终点(死亡/血栓栓塞/非计划血运重建)两组相似,无交互作用。
  • 胃肠道出血风险在双联与三联间无交互作用(交互P值0.84和0.62)。

核心结论

  • 在房颤PCI术后患者中,达比加群110mg和150mg双联治疗较华法林三联治疗降低大出血或临床相关非大出血风险,无论基线是否使用质子泵抑制剂。
  • 复合疗效终点在达比加群双联与华法林三联间相似,无论是否使用质子泵抑制剂。

研究设计与样本

  • RE-DUAL PCI试验的事前亚组分析,随机分配2725例房颤PCI术后患者至达比加群双联(110或150mg每日两次,联合氯吡格雷或替格瑞洛)或华法林三联(联合氯吡格雷或替格瑞洛,以及阿司匹林1-3个月)。
  • 分析基于基线质子泵抑制剂使用情况,评估首次大出血或临床相关非大出血、所有胃肠道出血及复合疗效终点。

主要发现

  • 共分析2678例患者,其中1641例(61.3%)基线使用质子泵抑制剂。
  • 达比加群110mg和150mg双联治疗较华法林三联治疗降低大出血或临床相关非大出血风险,无论是否使用质子泵抑制剂(所有交互P值>0.05)。
  • 胃肠道出血方面,研究治疗与质子泵抑制剂使用间无交互作用(达比加群110mg和150mg双联对比华法林三联的交互P值分别为0.84和0.62)。
  • 复合疗效终点风险在达比加群双联与华法林三联间相似,无论是否使用质子泵抑制剂。

临床怎么用

  • 对于房颤PCI术后患者,达比加群双联治疗可考虑作为华法林三联的替代方案,无论是否使用质子泵抑制剂。
  • 质子泵抑制剂的使用不影响达比加群双联治疗相对于华法林三联的出血风险降低效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: In patients with atrial fibrillation following percutaneous coronary intervention, if a proton pump inhibitor is used, could that allow the use of warfarin triple therapy, or is there additional reduction in bleeding while using it with dual therapy? METHODS: The RE-DUAL PCI trial randomized 2725 patients with atrial fibrillation post-percutaneous coronary intervention to dabigatran dual therapy (110 or 150 mg twice daily, with clopidogrel or ticagrelor) or warfarin triple therapy (with clopidogrel or ticagrelor, and aspirin for 1-3 months). This prespecified subgroup analysis evaluated risks of a first major bleeding event or clinically relevant non-major bleeding event, all gastrointestinal bleeding, and a composite efficacy endpoint of all-cause mortality/thromboembolic event or unplanned revascularization according to baseline use of a proton pump inhibitor. RESULTS: Of 2678 analyzed patients, 1641 (61.3%) were receiving a proton pump inhibitor at baseline. Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy regardless of proton pump inhibitor use, with comparable risk of the composite efficacy endpoint (all interaction p values > 0.05). For gastrointestinal bleeding, no interaction was observed between study treatment and proton pump inhibitor use (interaction p values 0.84 and 0.62 for dabigatran 110 and 150 mg dual therapy, respectively, vs warfarin triple therapy). CONCLUSIONS: Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy, regardless of proton pump inhibitor use at baseline, in patients with atrial fibrillation who underwent percutaneous coronary intervention. Risk of the composite efficacy endpoint appeared to be similar for dabigatran dual therapy vs warfarin triple therapy in patients receiving/not receiving a proton pump inhibitor. CLINICALTRIALS. GOV UNIQUE IDENTIFIER: NCT02164864.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Nicolau JC, Bhatt DL, Hohnloser SH, et al. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs. 2020. PMID: 32562206. doi:10.1007/s40265-020-01323-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。